Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

• Main Authors: Marina Talamonti (Author), Giovanna Malara (Author), Ylenia Natalini (Author), Federico Bardazzi (Author), Andrea Conti (Author), Andrea Chiricozzi (Author), Cristina Mugheddu (Author), Paolo Gisondi (Author), Stefano Piaserico (Author), Gianluca Pagnanelli (Author), Paolo Amerio (Author), Concetta Potenza (Author), Franca Cantoresi (Author), Maria Concetta Fargnoli (Author), Anna Balato (Author), Francesco Loconsole (Author), Annamaria Offidani (Author), Claudio Bonifati (Author), Francesca Prignano (Author), Marta Bartezaghi (Author), Alice Rausa (Author), Elisabetta Aloisi (Author), Roberto Orsenigo (Author), Antonio Costanzo (Author)
• Format: Book
• Published: Medical Journals Sweden, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period...